←
Alex Bataller754 posts
Alex Bataller avatar

Alex Bataller

@AlexBataller

MD PhD. Assistant Professor #Leukemia @MDAndersonNews, Houston (TX). From Barcelona | @hematoclinicbcn. Ski and mountains. I hate all types of cheese.

◷ Joined February 2015▧ 67 Photos and videos
Mike Thompson, MD, PhD, FASCO avatar
⟳ Alex Bataller retweeted
Mike Thompson, MD, PhD, FASCO@mtmdphd·Jun 13

Whole Genome Sequencing [WGS] Reveals Novel, Clinically Relevant Biomarkers Missed by Standards of Care for Pts w/ Myelodysplastic Syndrome [MDS] [Jun 11, 2026] @AlexBataller et al. #EHA2026 EHA-4897 PF656 library.ehaweb.org/eha/2026/… #MDSsm #leusm #cagenome @UTMDAnderson @TempusAI

Mike Thompson, MD, PhD, FASCO avatar
⟳ Alex Bataller retweeted
Mike Thompson, MD, PhD, FASCO@mtmdphd·Jun 12

Whole Genome Sequencing [WGS] Reveals Novel, Clinically Relevant Biomarkers Missed by Standards of Care for Pts w/ Myelodysplastic Syndrome [MDS] [Jun 11, 2026] @AlexBataller et al. #EHA2026 EHA-4897 PF656 library.ehaweb.org/eha/2026/… #MDSsm #leusm #cagenome @UTMDAnderson @TempusAI

Naveen Pemmaraju, MD avatar
⟳ Alex Bataller retweeted
Naveen Pemmaraju, MD@doctorpemm·Jun 8

👏👏👏Congratulations to our brilliant Leukemia Chief Fellow Dr .@r_sazevedo on being awarded 🥇 Best Overall Fellow of The Year Award at our Leukemia graduation! Very many Congratulations to each & all of our graduating fellows 👏!!!! @TapKadia @garciamanero 🙌

Post attachmentPost attachmentPost attachmentPost attachment
UT MD Anderson avatar
⟳ Alex Bataller retweeted
UT MD Anderson@UTMDAnderson·Jun 1

Whole genome sequencing revealed clinically relevant alterations missed by standard testing in MDS, identifying 21 novel high-confidence variants in 39% of cases, including key structural and prognostic drivers. Presented at #ASCO26 by Dr. Alex Bataller. @AlexBataller @garciamanero #EndCancer 9/12

Post attachment
Sanam Loghavi, MD صنم لغوی 🔬🧬 avatar
⟳ Alex Bataller retweeted
Sanam Loghavi, MD صنم لغوی 🔬🧬@sanamloghavi·Mar 11

🔑 KEY FINDING: 52% of patients showed immunophenotypic shifts after revumenib — often myeloid/stem-like → monocytic/myelomonocytic. Among MRD+ patients in remission, 67% had antigen expression changes vs. pre-treatment AML! 👇 @AlexBataller

Post attachment